FIGURE 8.
Description of (A) the median glucocorticoid (prednisone or equivalent) intake as mg/day at the start of canakinumab and at each follow-up visit, distinguishing according to the different disease pattern (systemic versus chronic-articular); (B) the total number of patients administered glucocorticoids (GC) at the different timepoints; (C) the total number of patients administered methotrexate (MTX) at the different timepoints.